391 related articles for article (PubMed ID: 24256244)
1. Induced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson's disease.
Beevers JE; Caffrey TM; Wade-Martins R
Biochem Soc Trans; 2013 Dec; 41(6):1503-8. PubMed ID: 24256244
[TBL] [Abstract][Full Text] [Related]
2. Cellular reprogramming: a new approach to modelling Parkinson's disease.
Hartfield EM; Fernandes HJ; Vowles J; Cowley SA; Wade-Martins R
Biochem Soc Trans; 2012 Oct; 40(5):1152-7. PubMed ID: 22988881
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease in a dish - Using stem cells as a molecular tool.
Badger JL; Cordero-Llana O; Hartfield EM; Wade-Martins R
Neuropharmacology; 2014 Jan; 76 Pt A():88-96. PubMed ID: 24035919
[TBL] [Abstract][Full Text] [Related]
4. Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells.
Li H; Jiang H; Zhang B; Feng J
J Parkinsons Dis; 2018; 8(4):479-493. PubMed ID: 30149462
[TBL] [Abstract][Full Text] [Related]
5. Modeling Parkinson's disease using induced pluripotent stem cells.
Byers B; Lee HL; Reijo Pera R
Curr Neurol Neurosci Rep; 2012 Jun; 12(3):237-42. PubMed ID: 22538490
[TBL] [Abstract][Full Text] [Related]
6. Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations.
Momcilovic O; Sivapatham R; Oron TR; Meyer M; Mooney S; Rao MS; Zeng X
PLoS One; 2016; 11(5):e0154890. PubMed ID: 27191603
[TBL] [Abstract][Full Text] [Related]
7. Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation.
Chung SY; Kishinevsky S; Mazzulli JR; Graziotto J; Mrejeru A; Mosharov EV; Puspita L; Valiulahi P; Sulzer D; Milner TA; Taldone T; Krainc D; Studer L; Shim JW
Stem Cell Reports; 2016 Oct; 7(4):664-677. PubMed ID: 27641647
[TBL] [Abstract][Full Text] [Related]
8. Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson's Disease Patients Display α-Synuclein Pathology and Abnormal Mitochondrial Morphology.
Diao X; Wang F; Becerra-Calixto A; Soto C; Mukherjee A
Cells; 2021 Sep; 10(9):. PubMed ID: 34572052
[TBL] [Abstract][Full Text] [Related]
9. The Progress of Induced Pluripotent Stem Cells as Models of Parkinson's Disease.
Kang JF; Tang BS; Guo JF
Stem Cells Int; 2016; 2016():4126214. PubMed ID: 26880962
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of ghrelin receptors on dopaminergic neurons in the substantia nigra contributes to Parkinson's disease-like motor dysfunction.
Suda Y; Kuzumaki N; Sone T; Narita M; Tanaka K; Hamada Y; Iwasawa C; Shibasaki M; Maekawa A; Matsuo M; Akamatsu W; Hattori N; Okano H; Narita M
Mol Brain; 2018 Feb; 11(1):6. PubMed ID: 29458391
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial alterations by PARKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines.
Shaltouki A; Sivapatham R; Pei Y; Gerencser AA; Momčilović O; Rao MS; Zeng X
Stem Cell Reports; 2015 May; 4(5):847-59. PubMed ID: 25843045
[TBL] [Abstract][Full Text] [Related]
12. What we can learn from iPSC-derived cellular models of Parkinson's disease.
Caiazza MC; Lang C; Wade-Martins R
Prog Brain Res; 2020; 252():3-25. PubMed ID: 32247368
[TBL] [Abstract][Full Text] [Related]
13. Decoding Parkinson's disease - iPSC-derived models in the OMICs era.
Krach F; Bogiongko ME; Winner B
Mol Cell Neurosci; 2020 Jul; 106():103501. PubMed ID: 32439399
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue.
Imaizumi Y; Okada Y; Akamatsu W; Koike M; Kuzumaki N; Hayakawa H; Nihira T; Kobayashi T; Ohyama M; Sato S; Takanashi M; Funayama M; Hirayama A; Soga T; Hishiki T; Suematsu M; Yagi T; Ito D; Kosakai A; Hayashi K; Shouji M; Nakanishi A; Suzuki N; Mizuno Y; Mizushima N; Amagai M; Uchiyama Y; Mochizuki H; Hattori N; Okano H
Mol Brain; 2012 Oct; 5():35. PubMed ID: 23039195
[TBL] [Abstract][Full Text] [Related]
15. Modeling Parkinson's Disease Using Induced Pluripotent Stem Cells.
Hu X; Mao C; Fan L; Luo H; Hu Z; Zhang S; Yang Z; Zheng H; Sun H; Fan Y; Yang J; Shi C; Xu Y
Stem Cells Int; 2020; 2020():1061470. PubMed ID: 32256606
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial Phenotypes in Parkinson's Diseases-A Focus on Human iPSC-Derived Dopaminergic Neurons.
Heger LM; Wise RM; Hees JT; Harbauer AB; Burbulla LF
Cells; 2021 Dec; 10(12):. PubMed ID: 34943944
[TBL] [Abstract][Full Text] [Related]
17. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
18. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.
Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y
FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Parkinson's Disease through Personalized Medicine and Induced Pluripotent Stem Cells.
Stoddard-Bennett T; Reijo Pera R
Cells; 2019 Jan; 8(1):. PubMed ID: 30621042
[TBL] [Abstract][Full Text] [Related]
20. Establishment of induced pluripotent stem cell lines derived from Parkinson's disease Mexican patients: A sporadic (UNAMi002-A) and a familial (UNAMi003-A) case carrying a mutation in PINK1.
Flores-Ponce X; López-Ornelas A; Escobedo-Avila I; Rodríguez-Violante M; Dávila-Ortiz de Montellano D; Cervantes-Arriaga A; Monroy-Jaramillo N; Campos-Romo A; Velasco I
Stem Cell Res; 2024 Apr; 76():103337. PubMed ID: 38359473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
